Modulation of the poliovirus receptor expression in malignant lymphocytes by epigenetic alterations

Journal of Immunotherapy

Volumn 34, Issue 4, 2011, Pages 353-361

  Wang, Wei ^a   Gao, Li ^a   Wang, Xinrong ^a   Kang, Huiyuan ^a   Li, Yonghui ^a   Wang, Lili ^a   Yu, Li ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

epigenetic modulation; malignant lymphocyte; NK cell; poliovirus receptor

Indexed keywords

AZACITIDINE; MESSENGER RNA; POLIOVIRUS RECEPTOR; UNCLASSIFIED DRUG; VIRUS RECEPTOR; VORINOSTAT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BURKITT LYMPHOMA; CANCER CELL; CONTROLLED STUDY; EPIGENETICS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; LYMPHATIC LEUKEMIA; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MYELOID LEUKEMIA; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AZACITIDINE; CELL LINE, TUMOR; CPG ISLANDS; CYTOTOXICITY, IMMUNOLOGIC; DNA METHYLATION; ENZYME INHIBITORS; EPIGENOMICS; GENE EXPRESSION REGULATION; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; K562 CELLS; KILLER CELLS, NATURAL; LEUKEMIA, LYMPHOID; LYMPHOMA; RECEPTORS, VIRUS; RNA, MESSENGER;

EID: 79955621874     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3182188017     Document Type: Article

References (38)

1. Biron CA. Activation and function of natural killer cell responses during viral infections. Curr Opin Immunol. 1997;9: 24-34. (Pubitemid 27098860)
2. Leibson PJ. Signal transduction during natural killer cell activation: inside the mind of a killer. Immunity. 1997; 6:655-661. (Pubitemid 27305728)
3. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097-2101.
4. Ruggeri L, Mancusi A, Capanni M, et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood. 2007;110:433-440. (Pubitemid 47026866)
5. Giebel S, Locatelli FW, Lamparelli T, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood. 2003;102: 814-819. (Pubitemid 36917769)
6. Beelen DW, Ottinger HD, Ferencik S, et al. Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term anti-leukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood. 2005;105:2594-2600. (Pubitemid 40387064)
7. Pende D, Spaggiari GM, Marcenaro S, et al. Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood. 2005;105:2066-2073. (Pubitemid 40731793)
8. Verheyden S, Demanet C. NK cell receptors and their ligands in leukemia. Leukemia. 2008;22:249-257. (Pubitemid 351250528)
9. Moretta A, Biassoni R, Bottino C, et al. Natural cytotoxicity receptors that trigger human NK-cell-mediated cytolysis. Immunol Today. 2000;21:228-234. (Pubitemid 30259028)
10. Shibuya A, Campbell D, Hannum C, et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity. 1996;4:573-581. (Pubitemid 26233311)
11. Wu J, Song Y, Bakker ABH, et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science. 1999;285:730-732.
12. Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol. 2003;3:781-790. (Pubitemid 37328656)
13. Sivori S, Parolini S, Falco M, et al. 2B4 functions as a coreceptor in human natural killer cell activation. Eur J Immunol. 2000;30:787-793. (Pubitemid 30216250)
14. Fuchs A, Cella M, Giurisato E, et al. Cutting edge: CD96 (Tactile) promotes NK cell-target cell adhesion by interacting with the Poliovirus receptor (CD155). J Immunol. 2004;172: 3994-3998. (Pubitemid 38375210)
15. Bottino C, Castriconi R, Pende D, et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands fro the human DNAM-1 (CD226) activating molecule. J Exp Med. 2003;198:557-567. (Pubitemid 37040390)
16. Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress inducible MICA. Science. 1999;285:727-729.
17. Cosman D, Mulberg J, Sutherland C, et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity. 2001;14:123-133. (Pubitemid 32206515)
18. Pende D, Rivera P, Marcenaro S, et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res. 2002;62:6178-6186. (Pubitemid 35244469)
19. Nowbakht P, Ionescu MC, Rohner A, et al. Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias. Blood. 2005;105:3615-3622. (Pubitemid 40628208)
20. Salih HR, Antropius H, Gieseke F, et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood. 2003;102:1389-1396. (Pubitemid 36988048)
21. Giles FJ. Novel agents for the therapy of acute leukemia. Curr Opin Oncol. 2002;14:3-9. (Pubitemid 34072956)
22. Melnick A. Predicting the effect of transcription therapy in hematologic malignancies. Leukemia. 2005;19:1109-1117. (Pubitemid 40945991)
23. Hoshino K, Yang H, Sanchez-Gonzalez B, et al. Detection of Aberrant DNA Methylation in Acute Lymphocytic Leukemia (ALL) Using a Real-Time Polymerase Chain Reaction (PCR) assay. Blood (ASH Annual Meeting Abstracts). 2004;104: Abstract 998.
24. Garcia-Manero G, Bueso-Ramos C, Daniel J, et al. DNA methylation patterns at relapse in adult acute lymphocytic leukemia. Clin Cancer Res. 2002;8:1897-1903. (Pubitemid 34633752)
25. Romanski A, Bug G, Becker S, et al. Mechanism of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia. Exp Hematol. 2005;33:344-352. (Pubitemid 40261316)
26. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166-178. (Pubitemid 43076714)
27. Kolb HJ, Schmid C, Barrett AJ, et al. Graft-versus-Leukemia reactions in allogeneic chimeras. Blood. 2004;103:767-776. (Pubitemid 38129531)
28. Slavin S, Naparstek E, Nagler A, et al. Allogeneic cell therapy for relapsed leukemia after bone marow transplantation with donor peripheral blood lymphocytes. Exp Hematol. 1995;23: 1553-1562. (Pubitemid 26034083)
29. Marten A, Renoth S, Heinicke T, et al. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum Gene Ther. 2003;14:483-494. (Pubitemid 36403540)
30. Montagna D, Maccario R, Montini E, et al. Generation and ex vivo expansion of cytotoxic T lymphocytes directed toward different types of leukaemia or myelodysplastic cells using both HLA-matched and partially matched donors. Exp Hematol. 2004;31:1031-1038. (Pubitemid 37329746)
31. Osman Y, Takahashi M, Zheng Z, et al. Activation of autologous or HLA-identical sibling cytotoxic T lymphocytes by blood derived dendritic cells pulsed wih tumor cell extracts. Oncol Rep. 1999;6:1057-1063.
32. Blair A, Rowbottom AW, Browne SJ, et al. An optimized biphasic culture system for the generation of functional dendritic cells from patients with acute lymphoblastic leukaemia at presentation and in clinical remission. Leukemia. 2001; 15:1596-1603. (Pubitemid 32994679)
33. Kohler T, Plettig R, Wetzstein W, et al. Cytokine-driven differentiation of blasts from patients with acute myelogenous and lymphoblastic leukemia into dendritic cells. Stem Cell. 2000;18:139-147. (Pubitemid 30176808)
34. Tsuchiya T, Hagihara M, Shimakura Y, et al. The generation of immunocomperent dendritic cells from CD 34 positive acute myeloid of lymphoid leukemia cells. Int J Hematol. 2002;75: 55-62. (Pubitemid 43014039)
35. Dolstra H, Fredrix H, Maas F, et al. A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. J Exp Med. 1999;189:301-308. (Pubitemid 29063251)
36. Muller MR, Grunebach F, Kayser K, et al. Expression of Her- 2/neu on acute lymphoblastic leukemias: implications for the development of immunotherapeutic approaches. Clin Cancer Res. 2003;9:3448-3453. (Pubitemid 37082743)
37. Imai C, Iwamoto S, Campana D. The main problem in ALL is their poor immunogenicity. Blood. 2005;106:376-383.
38. Klisovic MI, Maghraby EA, Parthun MR, et al. Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells. Leukemia. 2003;17:350-358. (Pubitemid 36266913)